All In Biotech

Drug Trial Radar · NCT01243944

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)

Last checked: Nov 20, 2026Latest source record: Mar 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 222 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

222

Actual

Start

Oct 27, 2010

Primary completion

Jan 15, 2014

Study completion Feb 9, 2018

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
Collaborators
Novartis Pharmaceuticals
First posted
Nov 19, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pivotal phase III trial (CINC424B2301) is designed to compare the efficacy and safety of ruxolitinib (INC424) to Best Available Therapy (BAT) in participants with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea (HU).

Conditions

  • Polycythemia Vera

Interventions

  • ruxolitinib tabletsDrug

    Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy

  • Best Available Therapy (BAT)Other

    Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Percentage of Participants Achieving a Primary Response at Week 32Time frame: 32 Weeks

Locations

102 sites in 18 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Pomona, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    Bridgeport, Connecticut

  • Site not named

    New Haven, Connecticut

  • Site not named

    Boynton Beach, Florida

  • Site not named

    Fort Myers, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Winter Park, Florida

  • Site not named

    Boise, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Lafayette, Louisiana

  • Site not named

    Scarborough, Maine

  • Site not named

    Baltimore, Maryland

  • Site not named

    Columbia, Maryland

  • Site not named

    Southfield, Michigan

  • Site not named

    Jefferson City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Morristown, New Jersey

  • Site not named

    Somerville, New Jersey

  • Site not named

    Charleston, South Carolina

  • Site not named

    Greenville, South Carolina

  • Site not named

    Nashville, Tennessee

  • Site not named

    Houston, Texas

  • Site not named

    Seattle, Washington

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Brisbane, Australia

  • Site not named

    Parkville, Australia

  • Site not named

    Tweed Heads, Australia

  • Site not named

    Antwerp, Belgium

  • Site not named

    Bruges, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Hamilton, Canada

  • Site not named

    Montreal, Canada

  • Site not named

    Toronto, Canada

  • Site not named

    Beijing, China

Showing 40 of 102 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.